Inactive Instrument

Company Genmab Nasdaq Copenhagen

Equities

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 10:59:45 2024-04-16 am EDT 5-day change 1st Jan Change
2,058 DKK +69.10% Intraday chart for Genmab +4.14% +14.24%

Business Summary

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (83.2%);

- income from research and development (12.4%);

- other (4.4%): primarily income from partnership agreement.

At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

Sales per Business

DKK in Million2022Weight2023Weight Delta
Antibody Therapeutics
100.0 %
14,595 100.0 % 16,474 100.0 % +12.87%

Sales per region

DKK in Million2022Weight2023Weight Delta
Denmark
97.4 %
14,595 100.0 % 16,053 97.4 % +9.99%
United States
2.3 %
0 0.0 % 380 2.3 % -
Japan
0.2 %
0 0.0 % 41 0.2 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 63 98-12-31
Director of Finance/CFO 46 06-12-31
Chief Operating Officer 53 20-03-22
Chief Tech/Sci/R&D Officer 51 16-12-31
Public Communications Contact - 19-03-10
Human Resources Officer 46 -
Corporate Officer/Principal 67 17-02-08
Corporate Officer/Principal 71 00-12-31
General Counsel 63 01-12-31

Members of the board

Members of the board TitleAgeSince
Chairman 63 16-12-31
Director/Board Member 73 03-10-31
Director/Board Member 63 15-12-31
Director/Board Member 59 22-03-28
Director/Board Member 57 14-12-31
Director/Board Member 73 14-12-31
Director/Board Member 51 19-03-28
Director/Board Member 49 21-12-31
Director/Board Member 50 21-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,122,964 65,373,793 ( 98.87 %) 744,170 ( 1.125 %) 98.87 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
4.896 %
3,237,113 4.896 % 979 M kr
Global Opportunities (GO) Capital Asset Management BV
3.556 %
2,351,225 3.556 % 711 M kr
ATP Fondsmaeglerselskab A/S
2.318 %
1,532,909 2.318 % 463 M kr
GENMAB A/S
1.595 %
1,054,745 1.595 % 319 M kr
600,497 0.9082 % 182 M kr
Industriens Pensionsforsikring A/S
0.7794 %
515,356 0.7794 % 156 M kr
Nykredit Bank A/S (Investment Management)
0.4817 %
318,516 0.4817 % 96 M kr
State Street Global Advisors Ltd.
0.2569 %
169,866 0.2569 % 51 M kr
Danske Bank A/S (Investment Management)
0.1986 %
131,323 0.1986 % 40 M kr
Sampension Administrationsselskab A/S
0.1744 %
115,344 0.1744 % 35 M kr
NameEquities%Valuation
AllianceBernstein LP
2.361 %
15,614,510 2.361 % 467 M kr
BlackRock Advisors LLC
0.6615 %
4,374,250 0.6615 % 131 M kr
Capital Research & Management Co. (International Investors)
0.6137 %
4,057,922 0.6137 % 121 M kr
Harding Loevner LP
0.4975 %
3,289,895 0.4975 % 98 M kr
Wellington Management Co. LLP
0.3583 %
2,369,331 0.3583 % 71 M kr
RBC Trust Co. Delaware Ltd.
0.2370 %
1,566,907 0.2370 % 47 M kr
Renaissance Technologies LLC
0.2261 %
1,494,800 0.2261 % 45 M kr
First Trust Advisors LP
0.1921 %
1,270,095 0.1921 % 38 M kr
Morgan Stanley Investment Management, Inc.
0.1647 %
1,089,097 0.1647 % 33 M kr
Wells Fargo Bank NA
0.1621 %
1,072,144 0.1621 % 32 M kr

Holdings

NameEquities%Valuation
1,054,745 1.60% 318,877,818 $

Company contact information

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com
address Genmab